Randomized Phase II trial of Cyclophosphamide and the Oral Poly (ADP-ribose) Polymerase Inhibitor Veliparib in Patients with Recurrent, Advanced Triple-Negative Breast Cancer

BACKGROUND: In tumors carrying BRCA mutations, DNA damage caused by standard cytotoxic chemotherapy can be potentiated by poly [ADP-ribose] polymerase (PARP) inhibitors, leading to increased cell death through synthetic lethality. Individuals carrying mutations in BRCA have an increased incidence of...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Invest New Drugs
Autori principali: Kummar, Shivaani, Wade, James L., Oza, Amit M., Sullivan, Daniel, Chen, Alice P., Gandara, David R., Ji, Jiuping, Kinders, Robert J., Wang, Lihua, Allen, Deborah, Coyne, Geraldine O’Sullivan, Steinberg, Seth M., Doroshow, James H.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2016
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4860030/
https://ncbi.nlm.nih.gov/pubmed/26996385
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-016-0335-x
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi